治疗性血管新生在心肌梗死后的应用进展  

Progress in application of therapeutic angiogenesis after myocardial infarction

作　　者：王天博 刘婷婷 孙芳玲 艾厚喜 郭德玉 王文 夏云峰[1] WANG Tian-bo;LIU Ting-ting;SUN Fang-ling;AI Hou-xi;GUO De-yu;WANG Wen;XIA Yun-feng(First Department of Cadres'Ward, First Affiliated Hospital, PLA General Hospital, Beijing 100048, China;Experimental Animal Center, Xuanwu Hospital of Capital Medical University, Beijing 100053,China)

机构地区：[1]解放军总医院第一附属医院干部一科,北京100048 [2]首都医科大学宣武医院实验动物室,北京100053

出　　处：《心脏杂志》2019年第2期217-221,共5页Chinese Heart Journal

基　　金：国家自然科学基金项目资助(81503049;81573633)

摘　　要：心肌梗死(MI)是一种急性缺血性心脏病,其病理特点是各种原因引起的心肌血管狭窄和堵塞,可并发心律失常、休克和心力衰竭,严重时危及患者生命。因此,促血管新生成为治疗MI的有效方法之一。近年来,随着对血管生长因子和血管新生研究的不断深入,治疗性血管新生已成为MI后治疗研究的新领域,在恢复血运重建方面起到重要作用。治疗性血管新生的方法主要包括蛋白质治疗、基因治疗和细胞治疗。本文就治疗性血管新生在MI后的应用做一综述。Myocardial infarction is an acute ischemic heart abnormality that can be complicated by arrhythmia, shock, and heart failure. In severe cases, it endangers the lives of many patients. Its pathological features are myocardial vascular stenosis and blockage caused by various reasons, which may lead to myocardial infarction. Angiogenesis is one of the effective methods for the treatment of myocardial infarction. In recent years, with research on angiogenic factors and angiogenesis, therapeutic angiogenesis has become a new specialized research field for post-myocardial treatment and potentially may play an important role in restoring revascularization. Methods for therapeutic angiogenesis include protein therapy, gene therapy, and cell therapy. This article reviews the application of therapeutic angiogenesis after myocardial infarction.

关 键 词：心肌梗死 生长因子 治疗性血管新生 

分 类 号：R542.2[医药卫生—心血管疾病]